SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.540
-0.410 (-10.38%)
Nov 7, 2024, 1:34 PM EST - Market open
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 12.4, with a low estimate of 6.00 and a high estimate of 25. The average target predicts an increase of 250.28% from the current stock price of 3.54.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SABS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +606.21% | Nov 7, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +210.73% | Oct 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $12 | Buy | Reiterates | $12 | +238.98% | Sep 12, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +606.21% | Sep 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $12 | Buy | Initiates | $12 | +238.98% | Aug 28, 2024 |
Financial Forecast
Revenue This Year
1.57M
from 2.24M
Decreased by -29.92%
Revenue Next Year
680.00K
from 1.57M
Decreased by -56.66%
EPS This Year
-3.65
from -7.64
EPS Next Year
-2.82
from -3.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.3M | 2.1M | 3.2M | ||
| Avg | 1.6M | 680,003 | 1.0M | ||
| Low | 1.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.2% | 33.8% | 363.2% | ||
| Avg | -29.9% | -56.7% | 50.0% | ||
| Low | -47.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.65 | -1.00 | -1.01 |
| Avg | -3.65 | -2.82 | -3.11 |
| Low | -3.60 | -4.91 | -5.55 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.